BJ
BJDX.US Bluejay Diagnostics Inc
- Market cap
- USD 2.92M
- P/E
- -
- P/B
- 0.31x
- ROE
- -112.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BJDX.US undervalued?
Graham numberThe Graham number of Bluejay Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bluejay Diagnostics Inc fundamental analysis
No fundamental analysis for Bluejay Diagnostics Inc yet.
Bluejay Diagnostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops S…
Full company profileBluejay Diagnostics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bluejay Diagnostics Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 75.00 | 249K | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -143K | -157K | -146K | 48.9K | -781K | -199K | -171K | - |
| Operating Income | -1.63M | -1.20M | -3.23M | -9.32M | -10.3M | -7.17M | -6.95M | -8.46M |
| EBITDA | -1.49M | -1.04M | -2.98M | -8.99M | -9.17M | -6.70M | -6.68M | -8.12M |
| Net Income | -758K | -1.13M | -3.73M | -9.30M | -9.95M | -7.72M | -6.85M | -8.34M |
| EPS | -38 | -57 | -119 | -1,180 | -1,162 | -673 | -61 | -7.11 |
| Balance Sheet | ||||||||
| Total Assets | 917K | 1.52M | 21.0M | 13.5M | 4.87M | 6.66M | 7.12M | 9.37M |
| Total Liabilities | 3.85M | 5.72M | 637K | 1.98M | 1.97M | 928K | 1.14M | 1.93M |
| Shareholders' Equity | -2.93M | -4.21M | 20.4M | 11.5M | 2.89M | 5.73M | 5.98M | 7.44M |
| Cash & Short-term Investments | 96.0K | 912K | 19.0M | 10.1M | 2.21M | 4.30M | 5.16M | 7.38M |
| Total Debt | 1.07M | 1.06M | - | 493K | 353K | 222K | 120K | 50.8K |
| Cash Flow | ||||||||
| Operating Cash Flow | -1.69M | -509K | -4.37M | -7.74M | -8.31M | -7.82M | -6.05M | -6.79M |
| Capital Expenditure | 6.02K | 23.9K | 23.9K | 1.20M | 704K | 307K | 174K | 478K |
| Free Cash Flow | -1.70M | -509K | -4.39M | -8.94M | -9.02M | -8.13M | -6.23M | -7.27M |
| Ratios | ||||||||
| ROE | - | - | -18.3% | -80.6% | -343.8% | -134.7% | -114.6% | -112.1% |
| ROA | -82.7% | -74.2% | -17.7% | -68.8% | -204.5% | -115.9% | -96.2% | -89.0% |
| Net Profit Margin | - | - | -4,972,914.7% | -3,733.1% | - | - | - | - |
| Debt to Equity | - | - | - | 0.04x | 0.12x | 0.04x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bluejay Diagnostics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 17.7K | 0.56 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:4 on Nov 3, 2026.
Who owns Bluejay Diagnostics Inc
- Insiders 2.03%
- Institutions 12.07%
- Public & others 85.90%
- Shares outstanding 1.12M
- Free float 1.09M
Top funds holding BJDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 39.6K | 6.55% | 0.00% | Sep 2026 |
Top institutions holding BJDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 131K | 2.93% | 0.00% | Jun 2026 |
| Heights Capital Management Inc | 35.4K | 0.79% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 27.1K | 0.61% | 0.00% | Jun 2026 |
| Bank of America Corp | 10.3K | 0.23% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 10.2K | 0.23% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.91K | 0.04% | +10.30% | Jun 2026 |
| L1 Global Manager Pty Ltd | 120.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | -66.67% | Jun 2026 |
| Sabby Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Bluejay Diagnostics Inc company profile
- Company name
- Bluejay Diagnostics Inc
- Ticker
- BJDX.US
- Exchange
- USA Stocks
- Listed since
- Nov 10, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6
- Fiscal year end
- December
- Address
- 360 Massachusetts Avenue, Acton, MA, United States, 01720
- Phone
- 844 327 7078
- Website
- bluejaydx.com
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Bluejay Diagnostics Inc management
4- Mr. Indranil DeyPrincipal Financial, Accounting & Executive Officer, President, CEO and Director · born 1963
- Mr. Kevin VanceChief Commercial Officer · born 1958
- Mr. Mark W. Feinberg M.D., Ph.D.Chief Medical Advisor
- Dr. Mark W. Feinberg M.D.Chief Medical Advisor